JP2004532846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532846A5 JP2004532846A5 JP2002581381A JP2002581381A JP2004532846A5 JP 2004532846 A5 JP2004532846 A5 JP 2004532846A5 JP 2002581381 A JP2002581381 A JP 2002581381A JP 2002581381 A JP2002581381 A JP 2002581381A JP 2004532846 A5 JP2004532846 A5 JP 2004532846A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- unsubstituted
- independently selected
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 125000001072 heteroaryl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 125000003107 substituted aryl group Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 9
- 125000000547 substituted alkyl group Chemical group 0.000 claims 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000002378 acidificating effect Effects 0.000 claims 4
- 125000000524 functional group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000003388 anti-hormonal effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28402601P | 2001-04-16 | 2001-04-16 | |
| PCT/US2002/012681 WO2002083624A1 (en) | 2001-04-16 | 2002-04-15 | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009122594A Division JP2009179641A (ja) | 2001-04-16 | 2009-05-20 | Ｃｘｃ−ケモカインレセプターリガンドとしての３，４−ジ−置換シクロブテン−１，２−ジオン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004532846A JP2004532846A (ja) | 2004-10-28 |
| JP2004532846A5 true JP2004532846A5 (enExample) | 2005-12-22 |
| JP4499993B2 JP4499993B2 (ja) | 2010-07-14 |
Family
ID=23088576
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002581381A Expired - Lifetime JP4499993B2 (ja) | 2001-04-16 | 2002-04-15 | Ｃｘｃ−ケモカインレセプターリガンドとしての３，４−ジ−置換シクロブテン−１，２−ジオン |
| JP2009122594A Pending JP2009179641A (ja) | 2001-04-16 | 2009-05-20 | Ｃｘｃ−ケモカインレセプターリガンドとしての３，４−ジ−置換シクロブテン−１，２−ジオン |
| JP2009278869A Expired - Lifetime JP5294418B2 (ja) | 2001-04-16 | 2009-12-08 | Ｃｘｃ−ケモカインレセプターリガンドとしての３，４−ジ−置換シクロブテン−１，２−ジオン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009122594A Pending JP2009179641A (ja) | 2001-04-16 | 2009-05-20 | Ｃｘｃ−ケモカインレセプターリガンドとしての３，４−ジ−置換シクロブテン−１，２−ジオン |
| JP2009278869A Expired - Lifetime JP5294418B2 (ja) | 2001-04-16 | 2009-12-08 | Ｃｘｃ−ケモカインレセプターリガンドとしての３，４−ジ−置換シクロブテン−１，２−ジオン |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP1818325B1 (enExample) |
| JP (3) | JP4499993B2 (enExample) |
| KR (2) | KR100952531B1 (enExample) |
| CN (2) | CN1990457A (enExample) |
| AR (1) | AR035825A1 (enExample) |
| AT (2) | ATE458715T1 (enExample) |
| AU (3) | AU2002311841B2 (enExample) |
| BR (1) | BRPI0208957B8 (enExample) |
| CA (1) | CA2444031C (enExample) |
| CY (2) | CY1109908T1 (enExample) |
| CZ (1) | CZ20032831A3 (enExample) |
| DE (2) | DE60220778T2 (enExample) |
| DK (2) | DK1818325T3 (enExample) |
| EC (1) | ECSP034809A (enExample) |
| ES (2) | ES2287284T3 (enExample) |
| HU (1) | HUP0401783A3 (enExample) |
| IL (3) | IL158262A0 (enExample) |
| MX (1) | MXPA03009441A (enExample) |
| MY (2) | MY138202A (enExample) |
| NO (2) | NO330790B1 (enExample) |
| NZ (3) | NZ543869A (enExample) |
| PE (1) | PE20021084A1 (enExample) |
| PL (2) | PL208928B1 (enExample) |
| PT (2) | PT1818325E (enExample) |
| RU (1) | RU2344123C9 (enExample) |
| SI (2) | SI1381590T1 (enExample) |
| SK (1) | SK287598B6 (enExample) |
| TW (2) | TW200736196A (enExample) |
| WO (1) | WO2002083624A1 (enExample) |
| ZA (1) | ZA200307905B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| EP1434775A1 (en) | 2001-10-12 | 2004-07-07 | Schering Corporation | 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| US8246969B2 (en) | 2001-11-16 | 2012-08-21 | Skinmedica, Inc. | Compositions containing aromatic aldehydes and their use in treatments |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| NZ535314A (en) * | 2002-03-18 | 2007-08-31 | Schering Corp | Combination treatments for chemokine-mediated diseases |
| GB0218326D0 (en) * | 2002-08-07 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| ES2321186T3 (es) | 2002-10-09 | 2009-06-03 | Schering Corporation | Dioxidos de tiadiazol y monoxidos de tiadiazol como ligandos de los receptores de quimioquinas cxc y cc. |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
| JP4705015B2 (ja) | 2003-04-03 | 2011-06-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | カルボニル化合物 |
| AR044027A1 (es) * | 2003-04-18 | 2005-08-24 | Schering Corp | Sintesis de 2-hidroxi-n,n-dimetil-3-[[2-[1(r) - (5-metil-2-furanil)propil]amino]- 3,4-dioxo-1-ciclobuten-1-il]amino]benzamida |
| NZ544756A (en) | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| GB0320983D0 (en) * | 2003-09-08 | 2003-10-08 | Biofocus Plc | Compound libraries |
| DE602004024798D1 (de) | 2003-09-23 | 2010-02-04 | Fermion Oy | Herstellung von quetiapin |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| MY139808A (en) | 2003-12-19 | 2009-10-30 | Schering Corp | Thiadiazoles as cxc-and cc-chemokine receptor ligands |
| JP4851943B2 (ja) | 2003-12-22 | 2012-01-11 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド |
| DE602005022986D1 (de) * | 2004-01-30 | 2010-09-30 | Schering Corp | Kristalline polymorphe eines cxc-chemokinrezeptorliganden |
| WO2005085197A1 (en) * | 2004-02-27 | 2005-09-15 | Schering Corporation | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
| EP1634573A1 (en) * | 2004-08-16 | 2006-03-15 | The Procter and Gamble Company | 2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof |
| CN101039652A (zh) | 2004-08-16 | 2007-09-19 | 宝洁公司 | 2－(氨基或取代的氨基)－5,6－取代的苯酚化合物，包含该化合物的染料组合物以及它们的应用 |
| WO2006101521A2 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| US7951805B2 (en) | 2004-09-20 | 2011-05-31 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| AU2005286647A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| AU2005286846A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as therapeutic agents |
| US8071603B2 (en) | 2004-09-20 | 2011-12-06 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| AR051026A1 (es) | 2004-09-20 | 2006-12-13 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| EP2096107A1 (en) | 2004-12-23 | 2009-09-02 | GPC Biotech AG | Derivatives of squaric acid with anti-proliferative activity |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| JP2009513563A (ja) | 2005-06-03 | 2009-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 |
| ATE486078T1 (de) | 2005-06-29 | 2010-11-15 | Schering Corp | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors |
| CN101253165A (zh) * | 2005-06-29 | 2008-08-27 | 先灵公司 | 作为cxc－化学活素受体配体的二取代的二唑 |
| DE102005035742A1 (de) * | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| HRP20161260T1 (hr) * | 2005-11-24 | 2016-11-18 | Dompé Farmaceutici S.P.A. | Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže |
| CN101448778A (zh) * | 2006-05-26 | 2009-06-03 | 艾博特公司 | Polo样激酶的抑制剂 |
| CL2007001714A1 (es) | 2006-06-12 | 2008-01-18 | Schering Corp | Composicion farmaceutica que comprende 2-hidroxi-n,n-dimetil-3-[[2-[[1(r)-5-metil-2-furanil)propil]amino]-3,4-dioxi-1-ciclobuteno-1-il]amino]benzamida y al menos un excipiente seleccionado de un agente humectante, un aglutinante, un disolvente y un desintegrante, util para tratar una enfermedad inflamatoria tal como artritis y asma. |
| RU2009103999A (ru) * | 2006-07-07 | 2010-08-20 | Шеринг Корпорейшн (US) | 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокиновых рецепторов |
| US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| US8183281B2 (en) | 2007-06-06 | 2012-05-22 | Novartis Ag | CXC-chemokine receptor ligands |
| CN101932553A (zh) * | 2007-07-03 | 2010-12-29 | 先灵公司 | 合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体 |
| US9006426B2 (en) * | 2008-06-24 | 2015-04-14 | Topotarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| WO2010063802A1 (en) * | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2011143430A1 (en) | 2010-05-12 | 2011-11-17 | Abbott Laboratories | Indazole inhibitors of kinase |
| FR2961695B1 (fr) * | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| PH12013501427B1 (en) | 2011-01-07 | 2019-02-13 | Allergan Inc | Melanin modification compositions and methods of use |
| ES2655942T3 (es) | 2011-09-02 | 2018-02-22 | Novartis Ag | Sal de colina de un compuesto anti-inflamatorio de ciclobutenodiona sustituida |
| FR2981935B1 (fr) * | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981936B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| CN103242210B (zh) * | 2012-02-09 | 2014-09-24 | 北京艾百诺科技有限公司 | 含有取代方酸的乙酸妙林酯及其应用 |
| US8916555B2 (en) | 2012-03-16 | 2014-12-23 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CN103382192A (zh) * | 2012-05-04 | 2013-11-06 | 同创医药(苏州)有限公司 | N-单取代哌嗪衍生物的制备 |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| CN103214327A (zh) * | 2013-03-22 | 2013-07-24 | 郑州泰基鸿诺药物科技有限公司 | 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法 |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| JP6450010B2 (ja) | 2014-12-23 | 2019-01-09 | アクシキン ファーマシューティカルズ インコーポレーテッド | ３，５−ジアミノピラゾールキナーゼ阻害剤 |
| FR3030515B1 (fr) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
| KR20200037857A (ko) * | 2017-08-14 | 2020-04-09 | 알러간, 인코포레이티드 | 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도 |
| WO2019067332A1 (en) | 2017-09-27 | 2019-04-04 | Merck Sharp & Dohme Corp. | COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST |
| JP7322036B2 (ja) | 2018-01-08 | 2023-08-07 | ケモセントリックス，インコーポレイティド | Ｃｃｒ６またはｃｘｃｒ２のアンタゴニストを用いて汎発性膿疱性乾癬を治療する方法 |
| CN116874466A (zh) | 2018-09-21 | 2023-10-13 | 辉瑞公司 | 用作ccr6抑制剂的n-取代二氧代环丁烯基氨基-3-羟基-吡啶甲酰胺 |
| CN110041309B (zh) * | 2019-04-04 | 2022-01-28 | 广东工业大学 | 一种2-羧基哌嗪连接的他克林-8-氨基(羟基)喹啉衍生物及制备与应用 |
| CN114727993B (zh) * | 2019-10-07 | 2025-11-14 | D·E·萧尔研究有限责任公司 | 作为Kv1.3钾SHAKER通道阻断剂的芳基亚甲基杂环化合物 |
| KR102710925B1 (ko) * | 2021-06-01 | 2024-09-27 | 부산대학교 산학협력단 | 신규 스퀘어아마이드 유도체 및 이의 용도 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0692915A (ja) * | 1992-07-28 | 1994-04-05 | Sumitomo Metal Ind Ltd | １，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途 |
| GB9312210D0 (en) * | 1993-06-14 | 1993-07-28 | Smithkline Beecham Plc | Chemical compounds |
| GB9316111D0 (en) * | 1993-08-04 | 1993-09-22 | Pfizer Ltd | Benzopyrans |
| US5354763A (en) * | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5466712A (en) * | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| DE69507639T2 (de) * | 1994-11-16 | 1999-09-02 | American Home Products Corp. | Diaminocyclobuten-3,4-dione |
| BR9709938A (pt) * | 1996-06-27 | 1999-08-10 | Smithkline Beecham Corp | Antagonistas dos receptores de il-8 |
| US5840764A (en) * | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| WO1998033763A1 (en) * | 1997-01-30 | 1998-08-06 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| US6211220B1 (en) * | 1998-11-23 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives |
| CN1334797A (zh) * | 1998-12-14 | 2002-02-06 | 美国家用产品公司 | 抑制经vla－4介导的白细胞粘附的3,4－二氨基－3－环丁烯－1,2－二酮衍生物 |
| AU761407B2 (en) * | 1998-12-16 | 2003-06-05 | Bayer Aktiengesellschaft | New biphenyl and biphenyl-analogous compounds as integrin antagonists |
| US6518283B1 (en) * | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| AR033803A1 (es) * | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| CN1454204A (zh) * | 2000-05-30 | 2003-11-05 | 史密丝克莱恩比彻姆公司 | Il－8受体拮抗剂 |
| ES2276926T3 (es) * | 2001-01-16 | 2007-07-01 | Smithkline Beecham Corporation | Antagonistas del receptor de il-8. |
| KR20030088044A (ko) * | 2001-03-30 | 2003-11-15 | 스미스클라인 비참 코포레이션 | 페놀-함유 화합물의 합성 방법 |
| NZ535314A (en) * | 2002-03-18 | 2007-08-31 | Schering Corp | Combination treatments for chemokine-mediated diseases |
-
2002
- 2002-04-15 CA CA2444031A patent/CA2444031C/en not_active Expired - Lifetime
- 2002-04-15 SI SI200230572T patent/SI1381590T1/sl unknown
- 2002-04-15 SI SI200230898T patent/SI1818325T1/sl unknown
- 2002-04-15 DK DK07010711.5T patent/DK1818325T3/da active
- 2002-04-15 NZ NZ543869A patent/NZ543869A/en not_active IP Right Cessation
- 2002-04-15 AU AU2002311841A patent/AU2002311841B2/en not_active Expired
- 2002-04-15 AR ARP020101371A patent/AR035825A1/es not_active Application Discontinuation
- 2002-04-15 HU HU0401783A patent/HUP0401783A3/hu unknown
- 2002-04-15 ES ES02739172T patent/ES2287284T3/es not_active Expired - Lifetime
- 2002-04-15 PL PL390082A patent/PL208928B1/pl unknown
- 2002-04-15 PL PL367129A patent/PL207255B1/pl unknown
- 2002-04-15 WO PCT/US2002/012681 patent/WO2002083624A1/en not_active Ceased
- 2002-04-15 DE DE60220778T patent/DE60220778T2/de not_active Expired - Lifetime
- 2002-04-15 CZ CZ20032831A patent/CZ20032831A3/cs unknown
- 2002-04-15 NZ NZ560453A patent/NZ560453A/en unknown
- 2002-04-15 ES ES07010711T patent/ES2340207T3/es not_active Expired - Lifetime
- 2002-04-15 MX MXPA03009441A patent/MXPA03009441A/es active IP Right Grant
- 2002-04-15 MY MYPI20021372A patent/MY138202A/en unknown
- 2002-04-15 PT PT07010711T patent/PT1818325E/pt unknown
- 2002-04-15 AT AT07010711T patent/ATE458715T1/de active
- 2002-04-15 MY MYPI20070922A patent/MY149050A/en unknown
- 2002-04-15 KR KR1020037013527A patent/KR100952531B1/ko not_active Expired - Fee Related
- 2002-04-15 DK DK02739172T patent/DK1381590T3/da active
- 2002-04-15 PT PT02739172T patent/PT1381590E/pt unknown
- 2002-04-15 NZ NZ529551A patent/NZ529551A/en not_active IP Right Cessation
- 2002-04-15 SK SK1288-2003A patent/SK287598B6/sk not_active IP Right Cessation
- 2002-04-15 EP EP07010711A patent/EP1818325B1/en not_active Expired - Lifetime
- 2002-04-15 EP EP02739172A patent/EP1381590B1/en not_active Expired - Lifetime
- 2002-04-15 RU RU2003133448/04A patent/RU2344123C9/ru not_active IP Right Cessation
- 2002-04-15 DE DE60235507T patent/DE60235507D1/de not_active Expired - Lifetime
- 2002-04-15 JP JP2002581381A patent/JP4499993B2/ja not_active Expired - Lifetime
- 2002-04-15 IL IL15826202A patent/IL158262A0/xx unknown
- 2002-04-15 AT AT02739172T patent/ATE365154T1/de active
- 2002-04-15 CN CNA2006101374093A patent/CN1990457A/zh active Pending
- 2002-04-15 CN CNB028119797A patent/CN1289471C/zh not_active Expired - Fee Related
- 2002-04-15 BR BR0208957-2 patent/BRPI0208957B8/pt not_active IP Right Cessation
- 2002-04-15 KR KR1020097026265A patent/KR20100008794A/ko not_active Ceased
- 2002-04-16 PE PE2002000318A patent/PE20021084A1/es not_active Application Discontinuation
- 2002-04-16 TW TW096102669A patent/TW200736196A/zh unknown
- 2002-04-16 TW TW091107670A patent/TWI316930B/zh active
-
2003
- 2003-10-02 IL IL158262A patent/IL158262A/en not_active IP Right Cessation
- 2003-10-09 ZA ZA2003/07905A patent/ZA200307905B/en unknown
- 2003-10-15 NO NO20034612A patent/NO330790B1/no not_active IP Right Cessation
- 2003-10-16 EC EC2003004809A patent/ECSP034809A/es unknown
-
2006
- 2006-08-24 AU AU2006203679A patent/AU2006203679A1/en not_active Abandoned
-
2007
- 2007-08-07 CY CY20071101059T patent/CY1109908T1/el unknown
-
2009
- 2009-05-20 JP JP2009122594A patent/JP2009179641A/ja active Pending
- 2009-10-25 IL IL201754A patent/IL201754A0/en unknown
- 2009-12-08 JP JP2009278869A patent/JP5294418B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-29 CY CY20101100380T patent/CY1109989T1/el unknown
- 2010-08-20 AU AU2010212484A patent/AU2010212484B2/en not_active Expired
-
2011
- 2011-01-12 NO NO20110050A patent/NO20110050L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532846A5 (enExample) | ||
| RU2003133448A (ru) | 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс- хемокинового рецептора | |
| JP6193922B2 (ja) | ハロアルキルヘテロアリールベンズアミド化合物 | |
| JP2004529911A5 (enExample) | ||
| JP2013510825A5 (enExample) | ||
| JP2012524111A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2006515858A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| JP5837936B2 (ja) | アルキルスルフィニル置換チアゾリド化合物 | |
| JP2014521653A5 (enExample) | ||
| JP2017504642A5 (enExample) | ||
| JP2019520402A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2013502431A5 (enExample) | ||
| JP2002516314A5 (enExample) | ||
| JP2020515583A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2007518809A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| CA2966423C (en) | Potent gamma-secretase modulators | |
| JP2020500869A5 (enExample) | ||
| JP2015503505A5 (enExample) | ||
| JP2017525744A5 (enExample) | ||
| EP0585500A1 (en) | Diaryl piperazineacetamides as antimuscarinic agents |